mesothelioma immunotherapy

DREAM Trial: Optimistic results from the first 31 patients

Earlier this month, during the most recent meeting of the American Society of Clinical Oncology (ASCO), first results from a new study are bound to bring hope to the mesothelioma community.
The aptly named DREAM study coming out of Australia is one of the first of its kind in mesothelioma, and so far, its results look […]


RECAP: Symposium tour kicks off in Minneapolis!

On Friday morning, we made our first stop on the 2018 International Symposium on Malignant Mesothelioma tour in Minneapolis, MN! Our executive director Mary Hesdoffer, NP and Science Advisory Board chair Dr. Tobias Peikert welcomed attendees to the one-day conference followed by an overview of our work in research, education, support and advocacy by director of […]


Updates from iMig – World trends in mesothelioma, global nursing panel with case studies, personalized therapy, and immunotherapy

Mesothelioma scientists and medical professionals convene at several conferences every year (one of which is our Symposium, the scientific portion of which will take place next year at the NIH) to update one another and present their most recent findings. These conferences are a crucial aspect of their work, as they provide an opportunity for […]


Mesothelioma Researcher Authors Journal Article on CAR T-cell Therapy

Mesothelioma researcher and Meso Foundation grant recipient Prasad S. Adusumilli, MD, FACS, FCCP, of the Memorial Sloan Kettering Cancer Center (MSKCC) was an author on the review article CAR T-cell therapy for lung cancer and malignant pleural mesothelioma recently published in Translational Research: The Journal of Laboratory and Clinical Medicine.
Dr. Adusumilli is a thoracic surgeon-scientist […]


BREAKING NEWS FROM ASCO: Promising Results Released from Mesothelioma Clinical Trial

This morning, Arnaud Scherpereel, MD, PhD, head of the Pulmonary and Thoracic Oncology Department at the University Hospital of Lille in France, presented the results of the IFCT-1501 MAPS-2 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study was sponsored by the French Cooperative Thoracic Intergroup (IFCT) with drugs and […]